Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

sandoz b.v. veluwezoom 22 1327 ah almere - efavirenz 600 mg/stuk - filmomhulde tablet - cellulose, microkristallijn (e 460) ; chinolinegeel aluminiumlak (e 104) ; croscarmellose natrium (e 468) ; hyprolose (e 463) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide rood (e 172) ; lactose 1-water ; macrogol 400 ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat (e 487) ; titaandioxide (e 171), - efavirenz

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

fresenius kabi nederland b.v. amersfoortseweg 10 e 3712 bc huis ter heide - kaliumchloride ; magnesiumchloride 1,5-water ; natriumacetaat 3-water (e 262) ; natriumchloride ; polyhydroxyethylzetmeel (mr 130.000) - oplossing voor infusie - natriumhydroxide (e 524) ; water, gezuiverd ; zoutzuur (e 507), - hydroxyethylstarch

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - natriumchloride 6,02 g/l; natriumacetaattrihydraat 4,63 g/l; kaliumchloride 0,3 g/l; magnesiumchloridehexahydraat 0,3 g/l; hydroxyethylzetmeel 60 g/l - oplossing voor infusie - 6 % - hydroxyethylzetmeel 60 mg/ml; magnesiumchloridehexahydraat 0.3 mg/ml; kaliumchloride 0.3 mg/ml; natriumacetaattrihydraat; natriumchloride 6.02 mg/ml - hydroxyethylstarch

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - natriumchloride 6,02 g/l; natriumacetaattrihydraat 4,63 g/l; kaliumchloride 0,3 g/l; magnesiumchloridehexahydraat 0,3 g/l; hydroxyethylzetmeel 60 g/l - oplossing voor infusie - hydroxyethylstarch

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - natriumchloride 6,02 g/l; natriumacetaattrihydraat 4,63 g/l; kaliumchloride 0,3 g/l; magnesiumchloridehexahydraat 0,3 g/l; hydroxyethylzetmeel 60 g/l - oplossing voor infusie - hydroxyethylstarch

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - natriumchloride 6,02 g/l; natriumacetaattrihydraat 4,63 g/l; kaliumchloride 0,3 g/l; magnesiumchloridehexahydraat 0,3 g/l; hydroxyethylzetmeel 60 g/l - oplossing voor infusie - hydroxyethylstarch

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - natriumchloride 6,02 g/l; natriumacetaattrihydraat 4,63 g/l; kaliumchloride 0,3 g/l; magnesiumchloridehexahydraat 0,3 g/l; hydroxyethylzetmeel 60 g/l - oplossing voor infusie - hydroxyethylstarch

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - natriumchloride 6,02 g/l; natriumacetaattrihydraat 4,63 g/l; kaliumchloride 0,3 g/l; magnesiumchloridehexahydraat 0,3 g/l; hydroxyethylzetmeel 60 g/l - oplossing voor infusie - hydroxyethylstarch

Europese Unie - Nederlands - EMA (European Medicines Agency)

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - antineoplastische middelen - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.

Europese Unie - Nederlands - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - precursorcel lymfoblastische leukemie-lymfoom - antineoplastische middelen - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.